[Prevention of atherothrombotic incidents. CHARISMA Study (The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance].
Erdmann
E
E
III. Medizinische Klinik, Universität zu Köln, Köln. erland.erdmann@uni-koeln.de
D000368:Aged; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D002423:Cause of Death; D000077144:Clopidogrel; D003328:Coronary Thrombosis / Q000401:mortality / Q000517:prevention & control; D004359:Drug Therapy, Combination; D017700:Embolism, Cholesterol / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D006801:Humans; D020766:Intracranial Embolism / Q000401:mortality / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin